Core Insights - Lisata Therapeutics is advancing its development portfolio centered around its product candidate, certepetide, with promising preliminary Phase 2b data for pancreatic cancer and multiple upcoming milestones expected over the next 12+ months [1][3][4] Development Portfolio Highlights - Certepetide is designed to enhance the delivery of anti-cancer agents to solid tumors and has shown favorable safety and clinical activity in trials [4][18] - The ASCEND trial, a Phase 2b study, has completed enrollment with 95 patients, showing a positive trend in overall survival and four complete responses in the treatment group [4][6] - Cohort B data from the ASCEND trial is anticipated in the coming months, with a total of 63 patients involved [4][5] - Other ongoing trials include BOLSTER for cholangiocarcinoma, CENDIFOX for pancreatic and colon cancers, and iLSTA for non-resectable pancreatic cancer, with data expected in mid-2025 [6][10][12] Financial Highlights - For the year ended December 31, 2024, Lisata reported revenue of $1.0 million, a decrease in operating expenses to $23.4 million from $25.7 million in 2023, and a net loss of $20.0 million [9][10][12] - Research and development expenses decreased to approximately $11.3 million, while general and administrative expenses were approximately $12.1 million [10][11] - As of December 31, 2024, the company had cash and marketable securities of approximately $31.2 million, which is expected to support operations into the second quarter of 2026 [13][18] Collaborations and Agreements - Lisata has entered into a collaboration with Kuva Labs to explore the use of certepetide in conjunction with imaging technology, receiving a $1.0 million upfront license fee and potential milestone payments [8][9] - The company is also collaborating with the University of Cincinnati and Valo Therapeutics for various studies involving certepetide [6][7]
Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update